Regulating Pharmaceutical Prices in the European Union

This case study aims to provide a better understanding of the necessity for regulation in the market for pharmaceuticals and to reveal the impacts of parallel trades in the European Union and how they may affect markets in the future. The pharmaceutical industry up to now has largely been regulated. Although the EU is a single market, it still has variable prices for pharmaceuticals. Consequently, the price gap and other EU-specific factors have created a great environment for parallel trades. The author has confined this study to the price regulations inside the EU before the enlargement in 2004.